{"title":"Retinopathy of prematurity: molecular pathology and therapeutic strategies.","authors":"Hadas Mechoulam, Eric A Pierce","doi":"10.2165/00129785-200303040-00004","DOIUrl":null,"url":null,"abstract":"<p><p>Retinopathy of prematurity (ROP) is an ischemia-induced proliferative retinopathy, which affects premature infants with low birth weight. It is a leading cause of visual impairment and blindness in children, and shares pathophysiological characteristics with other common ocular diseases such as diabetic retinopathy, central vein occlusion, and age-related macular degeneration. Pathologically similar inherited diseases such as Norrie disease suggest a possible genetic component in the susceptibility to ROP. The process of retinal neovascularization in ROP and in animal models of oxygen-induced retinopathy is complex, and involves angiogenic factors, such as vascular endothelial growth factor, and basement membrane components. Potential medical therapies for ROP, including modulators of angiogenic factors, inhibitors of basement membrane changes, endogenous inhibitors such as pigment epithelium derived factor, and anti-inflammatory drugs, have shown efficacy against neovascularization in several animal models. Some of these therapies are in clinical trials now for diabetic retinopathy and age-related macular degeneration, and in the future may prove efficacious for the treatment of ROP.</p>","PeriodicalId":72171,"journal":{"name":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2003-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2165/00129785-200303040-00004","citationCount":"28","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of pharmacogenomics : genomics-related research in drug development and clinical practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2165/00129785-200303040-00004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 28
Abstract
Retinopathy of prematurity (ROP) is an ischemia-induced proliferative retinopathy, which affects premature infants with low birth weight. It is a leading cause of visual impairment and blindness in children, and shares pathophysiological characteristics with other common ocular diseases such as diabetic retinopathy, central vein occlusion, and age-related macular degeneration. Pathologically similar inherited diseases such as Norrie disease suggest a possible genetic component in the susceptibility to ROP. The process of retinal neovascularization in ROP and in animal models of oxygen-induced retinopathy is complex, and involves angiogenic factors, such as vascular endothelial growth factor, and basement membrane components. Potential medical therapies for ROP, including modulators of angiogenic factors, inhibitors of basement membrane changes, endogenous inhibitors such as pigment epithelium derived factor, and anti-inflammatory drugs, have shown efficacy against neovascularization in several animal models. Some of these therapies are in clinical trials now for diabetic retinopathy and age-related macular degeneration, and in the future may prove efficacious for the treatment of ROP.
早产儿视网膜病变(Retinopathy of prematurity, ROP)是一种缺血诱发的增殖性视网膜病变,主要影响低出生体重早产儿。它是儿童视力损害和失明的主要原因,与其他常见的眼部疾病如糖尿病视网膜病变、中央静脉阻塞和年龄相关性黄斑变性具有相同的病理生理特征。病理上类似的遗传疾病,如诺里病,提示对ROP的易感性可能有遗传成分。在ROP和氧致视网膜病变动物模型中,视网膜新生血管的形成过程是复杂的,涉及血管生成因子,如血管内皮生长因子和基底膜成分。在一些动物模型中,潜在的治疗ROP的药物,包括血管生成因子调节剂、基底膜改变抑制剂、内源性抑制剂(如色素上皮衍生因子)和抗炎药物,已经显示出对新生血管的疗效。其中一些治疗方法目前正处于糖尿病视网膜病变和年龄相关性黄斑变性的临床试验中,将来可能被证明对ROP的治疗有效。